|
KMID : 1200020160400020099
|
|
Diabetes & Metabolism Journal
2016 Volume.40 No. 2 p.99 ~ p.114
|
|
|
An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass
|
|
:Chon Suk
:Gautier Jean-Francois Gautier
|
|
|
Abstract
|
|
|
|
Type 2 diabetes mellitus (T2DM) is a multifactorial disease with a complex and progressive pathogenesis. The two primary mechanisms of T2DM pathogenesis are pancreatic β-cell dysfunction and insulin resistance. Pancreatic β-cell dysfunction is recognized to be a prerequisite for the development of T2DM. Therapeutic modalities that improve β-cell function are considered critical to T2DM management; however, blood glucose control remains a challenge for many patients due to suboptimal treatment efficacy and the progressive nature of T2DM. Incretin-based therapies are now the most frequently prescribed antidiabetic drugs in Korea. Incretin-based therapies are a favorable class of drugs due to their ability to reduce blood glucose by targeting the incretin hormone system and, most notably, their potential to improve pancreatic β-cell function. This review outlines the current understanding of the incretin hormone system in T2DM and summarizes recent updates on the effect of incretin-based therapies on β-cell function and β-cell mass in animals and humans.
|
|
|
KEYWORD
|
|
|
Diabetes mellitus, Dipeptidyl peptidase-4 inhibitor, Glucagon-like peptide-1 receptor agonist, Incretins, Insulin-secreting
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
   
|